Abstract
In view of the serious clinical harm of preeclampsia and the lack of effective treatment methods, a PEG-modified lipid hybrid micelle was designed with a folic acid molecule on the surface, containing siRNA, targeted delivery to the placenta, interfering with the expression of sFlt-1 and treating preeclampsia. In this paper, the preparation and characterisation of lipid hybrid micelles were investigated in detail, the cytology in vitro and in vivo distribution, pharmacodynamics, safety and action mechanism of the preparation were studied, which laid a foundation for gene therapy of preeclampsia.
Keywords:
Disclosure statement
No potential conflict of interest was reported by the author(s).